Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
A number of other analysts also recently commented on ASND. Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd. TheStreet upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, Wedbush began coverage on Ascendis Pharma A/S in a report on Monday, September 26th. They issued an “outperform” rating and a $34.00 target price for the company.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down 5.43% during mid-day trading on Wednesday, hitting $19.00. The stock had a trading volume of 1,369,941 shares. The stock’s market cap is $478.67 million. Ascendis Pharma A/S has a 12-month low of $11.92 and a 12-month high of $21.79. The firm’s 50-day moving average price is $19.96 and its 200 day moving average price is $16.30.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative return on equity of 47.61% and a negative net margin of 818.32%. Equities analysts forecast that Ascendis Pharma A/S will post ($3.14) EPS for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.